Chardan Capital Analysts Reduce Earnings Estimates for FDMT

Key Points

• Chardan Capital has significantly lowered its FY2025 EPS estimate for 4D Molecular Therapeutics from ($3.07) to ($3.52), despite maintaining a "Buy" rating on the stock with a price target of $25.00.
• The company reported a quarterly EPS of ($0.98), falling short of the consensus estimate of ($0.88) and generating a revenue of only $0.01 million compared to the expected $0.52 million.
• 4D Molecular Therapeutics' average rating is currently a "Moderate Buy" with a consensus price target of $30.40, however, the company faces several weakened price targets from various financial firms.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Investment analysts at Chardan Capital decreased their FY2025 earnings per share (EPS) estimates for shares of 4D Molecular Therapeutics in a report issued on Tuesday, August 12th. Chardan Capital analyst Y. Livshits now expects that the company will post earnings per share of ($3.52) for the year, down from their previous forecast of ($3.07). Chardan Capital has a "Buy" rating and a $25.00 price objective on the stock. The consensus estimate for 4D Molecular Therapeutics' current full-year earnings is ($2.84) per share.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.10). The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.52 million. 4D Molecular Therapeutics had a negative return on equity of 40.15% and a negative net margin of 594,375.81%.

Several other research analysts have also recently weighed in on the company. The Goldman Sachs Group lowered their price objective on 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Barclays lowered their price objective on 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a research report on Friday, May 9th. Roth Capital dropped their price target on 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research note on Tuesday, August 12th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Thursday, August 14th. Eight research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, 4D Molecular Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $30.40.

4D Molecular Therapeutics Trading Up 4.3%

FDMT stock traded up $0.28 during trading hours on Friday, hitting $6.85. 635,164 shares of the stock were exchanged, compared to its average volume of 885,082. The firm has a market capitalization of $319.91 million, a P/E ratio of -1.94 and a beta of 2.83. The company has a 50-day simple moving average of $4.77 and a two-hundred day simple moving average of $4.16. 4D Molecular Therapeutics has a 12 month low of $2.23 and a 12 month high of $17.41.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BVF Inc. IL grew its position in 4D Molecular Therapeutics by 1.5% in the second quarter. BVF Inc. IL now owns 4,629,289 shares of the company's stock valued at $17,175,000 after acquiring an additional 68,000 shares during the last quarter. Vanguard Group Inc. grew its position in 4D Molecular Therapeutics by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 2,860,508 shares of the company's stock valued at $15,933,000 after acquiring an additional 92,791 shares during the last quarter. Federated Hermes Inc. grew its position in 4D Molecular Therapeutics by 33.4% in the second quarter. Federated Hermes Inc. now owns 1,667,338 shares of the company's stock valued at $6,186,000 after acquiring an additional 417,157 shares during the last quarter. Millennium Management LLC grew its position in 4D Molecular Therapeutics by 15.0% in the first quarter. Millennium Management LLC now owns 1,633,987 shares of the company's stock valued at $5,278,000 after acquiring an additional 213,264 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in 4D Molecular Therapeutics by 159.5% in the fourth quarter. JPMorgan Chase & Co. now owns 820,069 shares of the company's stock valued at $4,568,000 after acquiring an additional 504,086 shares during the last quarter. Institutional investors own 99.27% of the company's stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.